SUPPLEMENTARY DATA MATERIALS AND METHODS
Antibodies and other reagents -Human recombinant interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNFα), connective tissue growth factor (CTGF), Wnt-inducible soluble protein 2 (WISP2) and transforming growth factor beta 1 (TGFβ1) proteins were purchased from Peprotech Inc. (Quebec, Canada). We obtained rabbit polyclonal antibodies for Collagen 2 (ab34712), MMP-13 (ab39012), Cox2 (ab15191), Oct4 (ab18976), Nanog (ab106465), CTGF (ab6995), rabbit monoclonal for MMP-3 (ab52915) and mouse monoclonal antibodies for Galectin 3 (ab2785) and β-actin (ab6276) were purchased from Abcam Inc. (CA, USA). Goat polyclonal Brachyury antibody (sc-17743) and rabbit polyclonal antibodies for Aggrecan (sc-25674), TIMP-1 (sc-5538), ADAMTS-4 (sc-25582), TNFα (sc-8301), TGFβ1 (sc-146) and mouse monoclonal WISP2 (sc-514070) were obtained from Santa Cruz Biotechnology Inc. (CA, USA).
RNA isolation and Real Time PCR-Total RNA was isolated from human degenerative disc NP cells (H1 / H2 / H3) treated with IL-1β (10 ng/mL), TNFα (50 ng/mL), CTGF (100ng/mL), TGFβ1 (10 ng/mL) or a combination of CTGF (100 ng/mL) and TGFβ1 (10 ng/mL) using RNAeasy extraction kit (Cat#74134, Qiagen) and quantified using a Nanodrop spectrophotometer. Total RNA (~ 400ng) was reverse-transcribed using RT 2 First Strand Kit (Cat#330401, Qiagen) following the manufacturer's instructions for preparing cDNA. Effect of treatment on ECM genes including collagen 2, HAPLN1, versican, thrombospondin 1 (Thbs1), MMP-13 and Cox2 was evaluated using real time PCR performed on ABI 7900HT 384-well Fast block machine.
Cell viability and cell proliferation assays -Nucleus pulposus cells (rat, bovine and human) in passage (P2), were plated in 96-well flat bottom plates in order to evaluate the effect of treatment with growth factors in cell viability and proliferation assays. Rat NP cells (passage, P2) were treated with CTGF, WISP-2 and TGFβ1 in a dose (1 ng/mL -100 ng/mL) and time dependent manner (24 hrs -96 hrs) to determine the optimum dose and time for the assessment of these growth factors on viability. Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, USA) as described earlier 49 . We used a BrdU -ELISA (colorimetric) assay (Cat# ab126556, Abcam) for determining the effect of treatment with CTGF (100 ng/mL) or TGFβ1 (10 ng/mL) on human and rat NP cells (healthy / injured) following the manufacturer's instructions. Briefly, NP cells were treated with CTGF (100 ng/mL) or TGFβ1 (10 ng/mL) alone or in combination for 48 hrs following addition of BrdU reagent O/N in each well. Incorporated BrdU in DNA of proliferating cells was determined using anti-BrdU antibody and quantified by ELISA as per the manufacturer's instructions.
Apoptosis assays -Inflammation induced apoptosis in NP cells (rat and human) was determined using Caspase 3/7 and Caspase 9 specific Lumi-Glo assays (Promega, Madison) . Briefly, NP cells were plated and treated with either IL-1β (10 ng/mL) alone or in combination with TNFα (50 ng/mL) only or in presence of CTGF (100 ng/mL) and TGFβ1 (10 ng/mL) for 48 hrs, followed by addition of specific reagents for Caspase 3/7 and Caspase 9 as per the manufacturer's instructions. Cells were incubated for another 4 hrs at 37 0 C, and plates were read in a multi-well luminescence plate reader. Fig. 2A ). Immunohistochemical analysis revealed no detectable expression of Brachyury (NC-specific marker) or Oct4 (stem cell marker) in human and bovine degenerative disc NPs ( Supplementary Fig.1A ). In contrast, strong nuclear expression of brachyury and Oct4 was observed in healthy, NCD canine and Wistar rat discs demonstrating the NC-and stem cell-rich NP (Supplementary Fig. 2A ). However, negative control tissue sections showed no immunostaining demonstrating the specificity of the antibodies ( Supplementary Fig. 2B ).
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FIGURE LEGENDS
Supplementary Fig. 1 were mixed (1:1) with control medium (serum free, phenol red free Hybridoma Media) and compared to no treatment controls (i.e. elution buffer + control medium (1:1).
Supplementary 
